What challenges does Novo Nordisk expect in 2026?

Novo Nordisk expects headwinds in its international operations in 2026 due to increasing competition and loss of market exclusivity.

How is Novo Nordisk addressing competition from Eli Lilly?

Novo Nordisk plans capacity expansion, higher-dose formulations, and new products to defend its market position against rivals like Eli Lilly.

Are fasting requirements a concern for Novo Nordisk's Wegovy pill?

Novo Nordisk's CEO stated that they have not seen evidence that fasting requirements for its oral semaglutide are a barrier to patient adoption.

Home / Business and Economy / Novo Nordisk Faces 2026 Headwinds Abroad

Novo Nordisk Faces 2026 Headwinds Abroad

14 Jan

•

Summary

Novo Nordisk anticipates significant international challenges in 2026.
CEO cites increasing competition as key factor for market share loss.
Company plans capacity expansion and new products to counter rivals.

Novo Nordisk Faces 2026 Headwinds Abroad

Novo Nordisk anticipates a challenging year for its international operations in 2026. CEO Mike Doustdar indicated that increased competition is expected to erode market share in regions where the company has historically held a strong position. This comes as market exclusivity for certain products expires, creating opportunities for rivals.

Doustdar acknowledged that while the United States market is stable, international markets represent the primary long-term volume opportunity for Novo Nordisk's lucrative diabetes and weight-loss franchise. The company is adapting to a dynamic obesity market, where cross-border and online sales are becoming more prominent, and is closely monitoring competition from entities like Eli Lilly.